Sheel Biotech IPO 2025: Price band, dates, listing

Sheel Biotech IPO: what happened and why it mattered

Sheel Biotech’s IPO opened for subscription on 30 September 2025 and closed on 3 October 2025. The issue drew attention because bidding was muted in the first two sessions, then jumped sharply by the final day based on the subscription data shared in the update. The IPO was priced in a tight band of ₹59 to ₹63 per share, and the total issue size was stated as ₹34.02 crore. The subscription dashboard also carried multiple snapshots for the same issue window, so it is important to read the numbers as “as of” specific timestamps rather than a single uniform figure. The last update time shown was 03 Oct 2025 at 04:45 PM. The allotment process was stated to be finalised on 6 October 2025, with listing indicated around 8 October 2025 on the NSE SME platform.

Key dates: opening, closing, allotment, listing

The bidding window was shown as 30/09/2025 to 03/10/2025. Multiple lines in the source reiterated the same open and close dates: 30-09-2025 to 03-10-2025. The allotment date was explicitly mentioned as 06-10-2025. A separate line stated the shares were “likely to list on NSE SME around October 8, 2025.” These dates matter for investors tracking when funds are blocked, when allotment status can be checked, and when trading begins.

Issue size, price band, and share count

The issue size was stated as ₹34.02 crore. The price band was ₹59 to ₹63 per share, with ₹63 also displayed as the upper end and referenced for investment calculations. The IPO was stated to offer 5,400,000 shares. These numbers set the framework for demand tracking across investor categories and the potential float available at listing.

Lot size and minimum investment: two figures shown

The data includes two different lot-size references. One section mentions a lot size of 4,000 shares and shows “₹2,52,000 / 2 lots (4,000 shares)” as the retail maximum and also as the minimum investment for retail at the upper price. Another table lists a lot size of 2,000 shares with a minimum investment of ₹2,36,000 and the same price range of ₹59 to ₹63.

Because both figures appear in the provided material, readers should rely on the final exchange and offer document terms when placing bids through their broker platform. The retail maximum displayed was 4,000 shares for ₹252,000. For HNI investors, the minimum investment was stated as 3 lots, or 6,000 shares, amounting to ₹3,78,000.

Subscription trend: low start, sharp final-day jump

The day-wise subscription series shows demand building slowly and then accelerating on Day 3. One snapshot shows total subscription at 0.06x on Day 1 (30-Sep-2025), rising to 0.34x on Day 2 (01-Oct-2025), and then jumping to 14.93x on Day 3 (03-Oct-2025). Another display in the same material shows total subscription as 14.87x (with retail 0.28x and HNI 0.12x) and a separate closing statement that the IPO was subscribed 15.97 times.

Taken together, the consistent signal across the provided tables is that the first two days were weak, followed by a strong close. The exact “closing” multiple differs across the included snapshots, so the safest reading is that the final-day demand was materially higher than the early trend.

Category-wise demand: Day 3 and closing snapshots

The category table “As of 03 Oct, 2025” reports Qualified Institutional Buyers (QIB) at 19.73x, Retail Individual Investors (RII) at 9.57x, and Non-Institutional Investors (NII) at 19.46x, with “Others” at 0x and total at 14.93x. Another line states that at closing the IPO was subscribed 15.97 times, with QIB at 19.73x and NII at 25.92x, while also stating the retail quota “was subscribed to 33.41%.”

These numbers indicate that institutional and non-institutional participation was reported as strong by the end of bidding in at least one closing snapshot, while retail participation is presented with two different figures across the material (9.56x or 33.41%). Investors tracking allocation probabilities typically look at the final category-wise subscription multiples shown by the exchange/registrar-linked data.

Share allocation and reservation breakdown

The IPO was stated to offer 5,400,000 shares, with category allocations shown as: 1,025,600 shares (18.9926%) to QIB, 769,200 (14.2444%) to NII, 1,794,800 (33.237%) to RII, and 33.53% to Others. The same block also lists “Anchor Investors” at 15,38,400 shares (28.49%), along with the other three categories.

A separate line also summarised quota guidance as Retail about 35%, NII about 15%, and QIB about 50%. Since the share-offer table provides explicit counts and percentages, those figures are the most concrete breakdown present in the text.

Subscription tables (as provided)

Allotment status: where and how to check

The allotment was stated to take place on 06-10-2025. The text says investors can check allotment status on the registrar’s website or on the NSE and BSE IPO allotment pages using the application number, PAN, or demat account details. The same section also notes that the bidding window was open till 3 October 2025, with allotment expected to be finalised on 6 October 2025.

How to apply: Kotak Neo, IIFL, Angel One routes

The application methods mentioned include applying online through the Kotak Neo website or Kotak Neo app using UPI or ASBA during the subscription period. IIFL Securities application steps were also provided, including applying via the IIFL Securities WhatsApp channel at +91 9892691696, as well as through IIFL’s web platform and the IIFL Markets app. Angel One steps were also listed: log in, navigate to IPO section, select Sheel Biotech IPO, enter lot size, submit UPI ID, and approve the UPI mandate.

These steps are operational details that help investors place bids correctly within the IPO window, but bid terms such as lot size and price are ultimately entered in the broker interface and must match the final offer terms.

Market impact: subscription swing and reported listing

The key market-facing development in the data is the sharp shift from low early subscription to strong final-day subscription multiples. Another clear market datapoint is the reported listing on the NSE at ₹91 per share, stated as a 44.44% premium over the ₹63 issue price. This listing figure, as presented, indicates strong secondary-market pricing relative to the upper end of the price band.

For retail participants, the material also includes early snapshot commentary that overall subscription was 0.34x at one point, implying demand was below supply at that time. But the later day-wise table shows a significant end-of-window surge, which is consistent with the practice of bids coming in closer to the close.

Company contact details provided

The registered office was listed as: Sheel Biotech Ltd., 8 Balaji Estates, 2nd Floor, Block-C, Guru Ravidas Marg, Kalkaji, South Delhi, New Delhi, 110019. The phone number provided was +91 88511 - 8980, and the email was compliance@sheelbiotech.com. These details are relevant for formal correspondence and offer-document references.

What to watch next

With the issue period ending on 03/10/2025, the stated next milestone was allotment on 06/10/2025, followed by a listing expected around 08/10/2025 on NSE SME. Investors tracking final outcomes typically focus on the allotment status update and the final basis of allotment. The material also presents multiple subscription snapshots, so the final exchange/registrar figures are the best reference point for any category-wise demand confirmation.